摘要
目的观察抗癌中药回生口服液对晚期非小细胞肺癌患者疗效及转化生长因子β1(TGF-β1)、血管内皮生长因子(VEGF)分泌的影响。方法 67例确诊的Ⅲb～Ⅳ晚期非小细胞肺癌患者随机分为两组,联合组(化疗+中药37例)和化疗组(30例),两组均选用非小细胞肺癌一线化疗方案酒石酸长春瑞滨+顺铂(NP)治疗2个周期后评价疗效并测定两组患者血清TGF-β1、VEGF水平。联合组在化疗当天服用回生口服液,连用21天。结果联合组和化疗组有效率分别为48.6%(18/37)和43.3%(13/30),两组差异无统计学意义(P>0.05);联合组治疗后血清TGF-β1、VEGF水平均显著下降,与化疗组比较TGF-β1(616.25±13.23)ng/L vs(435.99±10.11)ng/L;VEGF(127.33±6.29)ng/L vs(83.56±5.12)ng/L,两组比较差异有统计学意义(P<0.01);化疗组治疗前后血清TGF-β1、VEGF水平差异无统计学意义(P>0.05)。结论抗癌中药回生口服液辅助化疗治疗晚期非小细胞肺癌可显著降低血清中TGF-β1、VEGF的表达水平,降低肿瘤的免疫抑制作用,起到抑瘤、防止复发转移的作用。
Objective It is to observe the clinical significance of anticancer Chinese medicine Huishengkoufuye on non-small-cell lung cancer and its effects on transforming growth factor-β1 （TGF-β1） and vascular endothelial growth /aetor（VEGF）. Methods Sixty-seven patients with Ⅲb～Ⅳ non-small-cell lung cancer were chosen and randomly divided into two groups：combined group（chemotherapy plus Chinese medicine, n = 37）,simple chemotherapy group（ n = 30）. Both groups were treated with NP chemotherapy for two cycles and then the patients were evaluated in curative effect and their expression levels of TGF-β1, VEGF were detected. The patients of combined group were given Huishengkoufuye additionally from the first day of chemotherapy for 21 days. Results The effective rate in combined group and simple group were respectively 48.6%（18/37） and 43.30% （13/30）, there was no significant difference between two groups （ P 〉 0.05）. The expressions of TGF-131, VEGF in combined group decreased significantly as compared between before and after treatment, TGF-β1 （616.25 ±13.23） ng/L vs （435.99±10.11） ng/L; VEGF （127.33±6.29） ng/L vs （83.56±5.12） ng/L（ P 〈0.01）,and those of simple group had no significant changes （ P 〉 0.05）. Conclusion Anticancer Chinese drug HuisAengkoufuye combined with chemotherapy for assistance-treated non- small-cell lung cancer could decrease the expression levels of TGF-β1 and VEGF significantly and could down-regulate the tumor-induced immunosuppression. It plays an role in suppression and prevention of tumor recurrence and metastasis.
出处
《临床荟萃》
CAS
2013年第6期643-645,共3页
Clinical Focus
基金
河北省自然科学基金资助项目(C2011315002)
关键词
癌
非小细胞肺
植物制剂
转化生长因子β1
血管内皮生长因子类
cancer, non-small-cell lung
plant preparations
transforming growth factor-β1
vascular endothelial growth factor
